June 18th 2025
The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.
Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer
December 17th 2018This article reviews the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix, as well as its potential risks and benefits, particularly when it comes to cardiovascular health.